Sun Pharmaceutical Industries is reportedly exploring a funding mix for a potential $12 billion acquisition of Organon, the women's health and biosimilars company spun off from Merck in 2021. If completed, this would be the largest overseas acquisition by an Indian pharmaceutical company — dwarfing Sun Pharma's own Ranbaxy deal in 2014.

The market is focused on deal mechanics. But a closer look at Sun Pharma's own filings — and those of its competitors — reveals a more nuanced story.

Can Sun Pharma Afford a $12 Billion Deal?

On paper, Sun Pharma is in a strong financial position. Per their FY25 annual report, the company posted gross sales of ₹520 billion (up 9% YoY) with EBITDA of ₹153 billion — a healthy 29.4% margin. Adjusted earnings per share rose 19% to ₹49.9.

The balance sheet looks solid: a debt-equity ratio of 0.46, interest coverage of 49.6 times, and a current ratio of 2.6 as of FY24. Their FY24 annual report explicitly notes "reduction in debt and increase in Cash and Cash equivalents" as a driver of the improved current ratio.

But $12 billion is roughly ₹1 lakh crore — equivalent to more than 6.5 times Sun Pharma's annual EBITDA. Even with a mix of equity and debt, this deal would fundamentally change the company's leverage profile. Their debt-equity ratio would likely jump well above 1.0, and that comfortable 49.6x interest coverage would compress significantly.

Sun Pharma's FY24 annual report describes its strategy as a "pragmatic mix of organic and inorganic growth initiatives" supported by a "strong balance sheet providing flexibility for inorganic growth without significant leverage." A $12 billion deal is definitionally not "without significant leverage."

Why Organon Makes Strategic Sense — On Paper

Sun Pharma has been deliberately building a global specialty portfolio since acquiring DUSA Pharma in 2012. Their FY25 annual report shows international business accounts for 68% of revenue, with the US alone contributing 32%. Key specialty products like Ilumya (an IL-23 inhibitor for psoriasis) anchor the portfolio.

Organon would add women's health — a segment where Sun Pharma currently has limited presence — plus a biosimilar portfolio and a stable base of established brands generating predictable cash flows. Per Sun Pharma's filings, specialty medicines now account for 50% of pharmaceutical spending in the top 10 developed markets and are projected to reach 55% by 2028.

Here's What Nobody's Talking About: Who Wins If Sun Pharma Is Tied Up in Integration?

Large pharma acquisitions consume management attention for years. And Sun Pharma's rivals are not standing still.

Emcure Pharmaceuticals (EMCURE) has women's health as a "core pillar" of its India business, per its FY25 annual report. The company reported domestic revenues of ₹36,597 million in FY25, with 19 of its top 20 brands ranked among the top 3 in their respective therapeutic segments. If Sun Pharma diverts management bandwidth to integrating Organon, Emcure is best positioned to gain share in India's women's health market. Emcure separately announced it "eyes India growth and global deals amid strong demand" — clearly aiming to fill any vacuum. Biocon (BIOCON) stands to benefit from the market's growing validation of biosimilars. Per their Q2 FY25 quarterly results, biosimilars revenue reached ₹21,816 million for the quarter and ₹42,650 million for H1 FY25, growing steadily from ₹39,835 million in H1 FY24. If Sun Pharma absorbs Organon's biosimilar portfolio, it validates Biocon's core thesis that biosimilars are the future of affordable healthcare. As a focused biosimilar developer, Biocon could attract the capital that investors rotate out of Sun Pharma on leverage concerns. Ajanta Pharma (AJANTPHARM) offers the most interesting contrast. Per their FY25 annual report, the company generated revenue of ₹4,648 crore (up 10% YoY) with a 27% EBITDA margin and net profit of ₹920 crore. Their US generics business contributed 23% of total sales and grew 9% during the year. Ajanta operates with no acquisition-driven debt and a lean cost structure — the exact opposite of what Sun Pharma would look like post-Organon. Investors seeking pharma exposure with lower integration risk may rotate toward names like Ajanta.

What Retail Investors Should Do

Don't rush to trade on deal speculation — the headline says Sun Pharma is "exploring," not "executing." But the filings tell a clear story: Sun Pharma's balance sheet, while strong today, would be fundamentally transformed by a $12 billion deal. If you hold Sun Pharma, watch for details on the equity-versus-debt funding split. Heavy equity dilution would pressure EPS; heavy debt would risk the investment-grade profile.

If you're looking for pharma exposure without acquisition risk, the filings show Emcure (women's health leader), Biocon (biosimilars at scale), and Ajanta Pharma (US generics with 27% margins) all growing organically from positions of strength. Sometimes the biggest deal creates the biggest opportunity — for everyone else.

Data sourced from company filings on NSE via Xaro.